Cardiovascular effects of hormone therapy for prostate cancer

Androgen deprivation therapy (ADT) has been the mainstay of treatment for advanced prostate cancer for decades, and has been shown to control disease and improve symptoms. In addition, for men with high-risk localized or locally advanced prostate cancer, short-course ADT in combination with radiotherapy improves survival.

There is evidence that ADT increases cardiovascular risk, particularly in men with preexisting cardiovascular disease This increased risk may apply even with short-course ADT In an individual patient, the benefits of ADT should be balanced against the risk, and patients who require ADT should have risk factors for cardiovascular disease optimized There is some evidence to suggest that more contemporary methods of delivering ADT may reduce cardiovascular risk

Drug, healthcare and patient safety 2015 Jul 23*** epublish ***

Jason F Lester, Malcolm D Mason

Velindre Hospital, Whitchurch, Cardiff University, Heath Park, Cardiff, UK , Velindre Hospital, Whitchurch, Cardiff University, Heath Park, Cardiff, UK ; School of Medicine, Cardiff University, Heath Park, Cardiff, UK

PubMed     Full Text Article

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe